Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST
Company Participants
Atabak Mokari – CFO & Treasurer
Justin Gunn – President of Endocrinology
Roberto Vieira – President of Oncology
Joseph K. Belanoff – Co-Founder, President, CEO & Director
Charles Robb
William Guyer – Chief Development Officer
Conference Call Participants
Edward Nash – Canaccord Genuity Corp., Research Division
David Amsellem – Piper Sandler & Co., Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Hello, and welcome to the Corcept Therapeutics Q3 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. It is now my pleasure to introduce CFO, Atabak Mokari.
Atabak Mokari
CFO & Treasurer
Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the third quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.
Today’s call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC’s website.
Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our revenue in the third quarter of 2026 was $340.5 million, a 33% increase from the second quarter and
